Plain-English translation of NCT06576271 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new experimental medication called designed to help treat autoimmune diseases like systemic lupus erythematosus (SLE) and interstitial lung disease linked to connective tissue disorders. The study will check how safe this treatment is, how well people tolerate it, and how the body processes it. Researchers are enrolling healthy volunteers as well as patients with these specific conditions to understand if this medication could help.
Current treatments for lupus and connective tissue-related lung disease don't work well for everyone, and some patients experience serious side effects. This trial is testing whether this medication could offer a safer, more effective option for people living with these conditions.
You likely qualify if…
You likely don't qualify if…
Depending on which part of the study you join, you may receive injections of the experimental medication, a placebo (inactive treatment), or an existing approved medication for comparison. You will have regular clinic visits for blood tests, physical exams, heart monitoring, and lung imaging to track how the medication affects your body. The study involves different groups—some healthy volunteers, some with lupus, and some with lung disease—to ensure researchers understand how this treatment works across different populations.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
United States